[HTML][HTML] Intranasal drug administration in Alzheimer-type dementia: Towards clinical applications
R Taléns-Visconti, JV de Julián-Ortiz, O Vila-Busó… - Pharmaceutics, 2023 - mdpi.com
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
R Taléns-Visconti, JV de Julián-Ortiz… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood-brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications.
R Taléns-Visconti, JV de Julián-Ortiz, O Vila-Busó… - …, 2023 - europepmc.org
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
[PDF][PDF] Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
R Taléns-Visconti, JV de Julián-Ortiz, O Vila-Busó… - Microbiol. Rev, 2014 - roderic.uv.es
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
[PDF][PDF] Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
R Taléns-Visconti, JV de Julián-Ortiz, O Vila-Busó… - Microbiol …, 2014 - researchgate.net
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications.
R Taléns-Visconti, JV de Julián-Ortiz… - …, 2023 - search.ebscohost.com
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
[PDF][PDF] Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
R Taléns-Visconti, JV de Julián-Ortiz, O Vila-Busó… - Microbiol …, 2014 - academia.edu
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
R Taléns-Visconti, JV de Julián-Ortiz… - …, 2023 - search.proquest.com
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
[HTML][HTML] Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
R Taléns-Visconti, JV de Julián-Ortiz, O Vila-Busó… - …, 2023 - ncbi.nlm.nih.gov
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
[PDF][PDF] Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
R Taléns-Visconti, JV de Julián-Ortiz, O Vila-Busó… - Microbiol …, 2014 - academia.edu
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …
barrier and systemic adverse effects. Intranasal administration offers a direct route to the …